Exome sequencing is becoming widely popular and affordable, making it one of the most desirable methods for the identification of rare genetic variants for clinical diagnosis. Here, we report the clinical application of whole exome sequencing for the ultimate diagnosis of a ciliary chondrodysplasia case presented with an initial clinical diagnosis of Asphyxiating Thoracic Dystrophy (ATD, Jeune Syndrome). We have identified a novel homozygous missense mutation in WDR35 (c.206G > A), a gene previously associated with Sensenbrenner Syndrome, Ellis-van Creveld syndrome and Short-rib polydactyly syndrome type V. The genetic findings in this family led to the re-evaluation of the initial diagnosis and a differential diagnosis of Sensenbrenner Syndrome was made after cautious re-examination of the patient. Cell culture studies revealed normal subcellular localization of the mutant WDR35 protein in comparison to wildtype protein, pointing towards impaired protein-protein interaction and/or altered cell signaling pathways as a consequence of the mutated allele. This research study highlights the importance of including pathogenic variant identification in the diagnosis pipeline of ciliary chondrodysplasias, especially for clinically not fully defined phenotypes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmg.2017.08.019DOI Listing

Publication Analysis

Top Keywords

exome sequencing
12
differential diagnosis
8
diagnosis ciliary
8
ciliary chondrodysplasias
8
clinical diagnosis
8
sensenbrenner syndrome
8
diagnosis
7
syndrome
5
sequencing differential
4
chondrodysplasias example
4

Similar Publications

Developmental anomalies of the hearing organ, the cochlea, are diagnosed in approximately one-fourth of individuals with congenital. The majority of patients with cochlear malformations remain etiologically undiagnosed due to insufficient knowledge about underlying genes or the inability to make conclusive interpretations of identified genetic variants. We used exome sequencing for the genetic evaluation of hearing loss associated with cochlear malformations in three probands from unrelated families deafness.

View Article and Find Full Text PDF

Purpose: Melanoma brain metastases (MBMs) are a common, lethal complication of metastatic melanoma. Despite improvements in treatments, subsets of MBM patients experience rapid decline, and few prognostic biomarkers have been identified. An improved understanding of the molecular features specifically associated with MBM overall survival (OS) and intracranial progression free survival (PFS) could facilitate the development of more effective clinical management strategies.

View Article and Find Full Text PDF

[Identification of genetically determined chronic childhood cytopenia in the era of molecular medicine].

Orv Hetil

January 2025

1 Semmelweis Egyetem, Általános Orvostudományi Kar, Gyermekgyógyászati Klinika Budapest, Tűzoltó utca 7-9., 1094 Magyarország.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Stanford University, School of Medicine, Stanford, CA, USA.

Background: Recently, clonal hematopoiesis of indeterminate potential (CHIP) was found to be associated with a reduced risk of Alzheimer's disease (AD) and somatic mutations found in the blood of CHIP carriers were also in microglia-enriched brain samples (Bouzid et al., 2023, Nature Medicine). We aimed to validate this finding in a larger dataset, explore the effect across APOE genotypes, and examine the association of CHIP with age-at-onset.

View Article and Find Full Text PDF

Current joint practice guidelines (PG) on genetic counseling and testing for Alzheimer's disease (AD), published in 2011 by the National Society of Genetic Counselors (NSGC) and American College of Medical Genetics), recommend against clinical APOE genetic testing. These recommendations were largely followed, as seen in a survey of AD Research Centers in 2019 where only 7% of centers reported disclosure of APOE to research participants. However, because the risk of amyloid related imaging abnormalities (ARIA) associated with anti-amyloid therapy is increased for those with one or two copies of APOE e4, the FDA now endorses APOE testing for those considering this treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!